Kornimate/medical-research-clean huggingface dataset:
effect of intake of dehydrated nopal powder from highly mature cladodes on the lipid profile

Conditions: Overweight; Obesity; Dyslipidemia

Summary: background: opuntia ficus-indica is a plant from the cactus family (cactaceae) that is widespread and of great economic importance in mexico. it has been consumed as food since pre-hispanic times and is currently considered a nutraceutical. in this study, the effect of consumption of dehydrated nopal powder from highly mature cladodes (opuntia ficus-indica) on the lipid profile of overweight or obese patients diagnosed with dyslipidemia was investigated. methods: a 3-month prospective clinical trial was conducted in 35 overweight or obese patients with dyslipidemia. the sample was divided into three groups with a daily intake of 30 g of dietary fiber: group i received 5 g of dehydrated opuntia ficus-indica cladodes plus the standard normocaloric diet for dyslipidemia, group ii received 15 g plus the diet, and group iii followed only the diet.


Eligibility criteria:
inclusion criteria: * participants with dyslipidemia, confirmed by lipid meas-urement in blood chemistry * overweight or obesity * a cardiovascular risk factor associated with abdominal obesity exclusion criteria: * patients with a suspected diagnosis of primary dyslipidemia * diabetes * hypertension * thyroid disease were excluded from the study * patients with complex or severe disease such as heart failure, liver or kidney disease * pregnant or lactating women * indidividuals taking lipid-modifying drugs or hormone replacement therapy - patients with gastrointestinal problems and deficiencies

Keywords: opuntia ficus-indica dyslipidemia overweight obesity diet
the heartland study

Conditions: Pregnancy Related; Pregnancy Complications; Birth Defect; Gestational Age and Weight Conditions; Spontaneous Abortion; Miscarriage; Exposure to Herbicides

Summary: the heartland study is a prospective, observational study that will enroll up to 2,600 pregnant participants across the heartland states in the u.s.. the objective of the heartland study is to address major knowledge gaps concerning the health effects of herbicides on maternal and infant health. the study is being conducted to evaluate the associations between environmental exposures to herbicides during and after pregnancy and reproductive health outcomes. the study is measuring multiple biomarkers of herbicide exposure among pregnant midwesterners and their partners to evaluate associations with pregnancy and childbirth outcomes, epigenetic biomarkers of exposure, and child development.

during phase 1 of the study, newly pregnant mothers will be enrolled less than or equal to 20 weeks + 6 days gestation and followed through to the end of pregnancy. prenatal urine and buccal (cheek) samples will be collected to measure urinary herbicide exposure levels and to identify herbicide induced epigenetic biomarkers. pregnancy outcomes and fetal health will be documented and analyzed to further investigate potential effects of fetal exposure. indirect measures such as food and beverage consumption, workplace and household related chemical exposures, substance use, residential proximity to agricultural fields, and socioeconomic factors will be captured from questionnaires.

Eligibility criteria:
inclusion criteria: * pregnant persons ages 18 or older at time of consent who are ≤20+6 weeks pregnant. best clinical estimate of gestational age will be utilized for recruitment purposes. enrollment in the first trimester (≤ 13 + 6) is preferred, but anyone ≤ 20 +6 is permitted. * living in one of the 13 heartland study region states at the time of enrollment (arkansas, illinois, indiana, iowa, kansas, michigan, minnesota, missouri, nebraska, north dakota, ohio, south dakota, or wisconsin) optional inclusion of the putative biological father exclusion criteria: * participants who are not fluent in and/or do not fully understand, read, write, or speak the english language. * other inability to provide informed consent to participate

Keywords: pesticide exposure birth outcomes biomonitoring
epsom salt compresses to relieve perineal for postpartum care: a clinical trial

Conditions: Perineal Injury; Pain

Summary: the goal of this clinical trial is to determine if topical application of compresses soaked in 25% magnesium sulfate on painful perineum after birth is effective to alleviate pain. researchers will compare this treatment to a placebo, compresses soaked in water. participants will be invited to use their compresses if needed, for 15 minutes, up to four times a day, during their stay at the hospital after giving birth. they will also have to keep a diary of their usage and of their pain.

background: despite the high frequency of perineal trauma in obstetrics, management of perineal care and pain is highly variable, relying on very few studies, if any. treatment of the perineum with compresses soaked in a magnesium sulfate (epsom salt) solution has not previously been studied but is routinely used in some hospitals in quebec, canada. objectives: this study aims to determine whether compresses soaked in 25% magnesium sulfate in sterile water can alleviate perineal pain in women immediately after childbirth. population and intervention: women who have just given birth vaginally and report perineal or vulvar pain of 3/10 or more will be recruited and randomized into an intervention group receiving the treatment (compresses soaked in 25% magnesium sulfate) or a control group receiving a placebo (compresses soaked in water). methods: this multi-centric, double-blinded randomized clinical trial will be conducted in four hospitals in the province of quebec, canada. the investigators plan to recruit a total of 104 participants. participants will be instructed to apply the compresses on the vulva and perineum for 15 minutes, four times per day, if needed. they will be asked to score their pain before and after using the compresses for the length of their hospital stay, typically between 24 and 48 hours. secondary outcomes include analgesic use, incidence of complications, participant satisfaction, opinions on feasibility, and any adverse effects caused by the compresses. discussion: this randomized controlled trial will assess whether the treatment is more effective in relieving pain than the placebo. the study will also determine the safety and feasibility of this method for routine postnatal care. this study could contribute in the long term to the standardization of evidence-based practices for the management of postpartum perineal pain in canadian hospitals

Eligibility criteria:
inclusion criteria: * planned hospital stay at the mother-child unit of the hôpital de chicoutimi, hôpital charles-le moyne, or hôpital honoré-mercier * vaginal delivery with or without perineal tear, any degree of tear, including episiotomies * obtaining consent for the study * languages spoken: french, english or both exclusion criteria: * hemodynamic instability * surgical procedure such as a cesarean section * transfer to another hospital * transfer to another care unit * chronic use of narcotics * inability to complete the logbook * unsigned consent form
a study to assess pulsed inhaled nitric oxide vs placebo in subjects with mild or moderate covid-19

Conditions: COVID-19; Coronavirus; Coronavirus Infection

Summary: a randomized, double-blind, placebo-controlled study to assess the efficacy and safety of pulsed inhaled ino compared to placebo in subjects with covid-19.

this is a randomized, double-blind, placebo-controlled study to assess the efficacy and safety of pulsed ino compared to placebo in subjects with covid-19 who are hospitalized and require supplemental oxygen without assisted ventilation. subjects will be randomized to receive placebo or ino125 mcg/kg ideal body weight (ibw)/hour 24 hours daily up to 14 days or until resolution or discharge.

Eligibility criteria:
inclusion criteria: * signed informed consent * at least 18 years old * subjects must be hospitalized and have the following: * proven or high suspicion of sars-cov-2 infection and, * requiring oxygen supplementation defined as: * spo2 ≤ 92% regardless of supplemental oxygen (ie on room air or on oxygen), or * spo2 ≥ 92% on supplemental o2 and in the opinion of the investigator it is not safe to decrease or remove the supplemental oxygen * require supplemental oxygen of no more than 10 l/minute, and * radiologic suspected or proven covid-19 pneumonitis (chest x-ray or ct scan) * female subjects must have a negative pregnancy test * willing and able to comply with the treatment schedule and study procedures exclusion criteria: * participating in another clinical trial of an investigational treatment for covid-19 * methemoglobin \> 3% * evidence of severe multi organ failure * use of assisted ventilation prior to initiation of ino * pregnancy or positive pregnancy test pre-dose * open tracheostomy * chronic use of a nitric oxide donor agent such as nitroglycerin or drugs known to increase methemoglobin such as lidocaine, prilocaine, benzocaine, nitroprusside, isosorbide, or dapsone at screening * history or clinical evidence of systolic heart failure, left ventricular dysfunction (lvef \<40%) * subjects reporting massive hemoptysis associated with the current illness or with radiologically proven pulmonary embolus

Keywords: covid sars-cov-2 ino inopulse severe acute respiratory syndrome (sars) pneumonia severe acute respiratory syndrome coronavirus 2 sars-cov 2 covinox pulsed inhaled nitric oxide inhaled nitric oxide portable pulsed inhaled nitric oxide nitric oxide
insulin resistance and resisted exercise post burn

Conditions: Insulin Resistance

Summary: the main objective of the present study is to assess the effect of the resisted exercise on insulin resistance post burn.

a burn injury represents the fourth most common type of trauma globally, though it is associated with the most devastating consequences. severe burn injuries, encompassing 20% of the total body surface area (tbsa) in adults, present a unique challenge compared with other forms of trauma given the magnitude and persistence of systemic deregulation. indeed, an extensive inflammatory response develops immediately following a severe burn to promote wound healing. this period, known as the "ebb" phase, is comparable with a fight-or-flight response and lasts for the first 72-96 h post injury . moreover, burn-induced muscle catabolism places a significant burden on the recovery process, as a 10%-30% loss impairs immune responses and delays wound healing, thereby increasing the risk of infection, and a 40% loss becomes fatal. despite a mountainous effort to prevent muscle catabolism and wasting. therefore, a better understanding of the pathophysiology and consequences of burn-induced skeletal muscle wasting is pivotal to alleviating hyper metabolism and reducing morbidity and mortality patients with severe burns . hence, extensive burn injury produce clinical syndromes characterized in part by "insulin resistance, it is unclear if these insulin resistant states are identical. to test if the maximal biological effectiveness of insulin is altered in burned patients

Eligibility criteria:
inclusion criteria: * patients ranged from 18-35 years of age. * patients has waist hip ratio around 0.8 in female and 0.95 in male. * patient has body mass index (bmi around 25 kg/m2) (j obes weight loss ther ,2015). * patients has second degree thermal burn injury (superficial and deep partial thickness). * patients with around (20% - 40%) of total body surface area (tbsa) burned. * patients who are able to follow verbal commands. * patients will have upper limb and trunk burn. * patients with normal hemoglobin a1c (5.6 %). * patients should take diet rich protein, omega 3 and should have good sleep. * patients passed two months post severe burns exclusion criteria: * - potential participants were excluded if they reported a leg amputation, anoxic brain injury, psychological disorders, quadriplegia, or severe behavior or cognitive disorders history of heart disease, stroke, diabetes mellitus, or any condition that would prevent them from engaging in an exercise study. * patients with liver disease, pancreatic disease or any disease affects metabolism. * if they were already engaging in 2 or more planned exercise sessions per week. * patients with any medication to lower glucose levels. blood pressure and medications to lower lipid levels
rotation and movement system, postpartum cesarean sections

Conditions: Breast Feeding, Exclusive

Summary: in the first half hour of a cesarean advertisement, the service-oriented mother will not be mobile and will need support to get fit in bed and start getting started. the patient turning and movement system will provide a lot of convenience to the mother who does not have enough support. with the remote control system, the mother will be easily turned to the desired side in the bed and it will be ensured that she takes the desired position with less pain and more comfort.

while studies on the patient turning and movement system have been conducted on long-term bedridden patients, there is no scientific study examining its effects in the obstetric field. for the reasons mentioned above, the aim of this research is; the aim of this study is to investigate the effect of patient turning and movement system on postpartum early postpartum breastfeeding success, pain and postpartum comfort in puerperant women who delivered by cesarean section and to contribute to the literature.

Eligibility criteria:
inclusion criteria: * being between the ages of 18-35. * primiparity. * having a transverse cesarean section. * at least primary school graduate. * no high-risk pregnancy. * absence of any complications in the puerperal and newborn during the delivery and postnatal period exclusion criteria: * having an open wound on the body and/or an allergic disease diagnosis on the skin. * development of puerperal complications (bleeding, infection, fever). * at risk of convulsions; have diseases such as eclampsia, epilepsy. * having a body mass index above 40 (morbidly obese). * having any contraindications for breastfeeding. * having chronic opioid, antidepressant, and psychoactive drug use.

Keywords: pain midwife breast-feeding movement comfort
lifestyle management app for adults with diabetes type

Conditions: Diabetes Mellitus, Type 2

Summary: this study will evaluate whether the 12-week health coaching mobile application (liven) will succeed in enhancing lifestyle behaviors in adults with type 2 diabetes compared to typical treatment. the mobile application's viability will be assessed in 2 parts; the first part is testing easiness and friendliness of using liven by the patient and health coach. the second part is evaluating the suitability of liven education material for the patients and whether the coaching program results in enhancing lifestyle behaviors and blood sugar levels. the investigators hypothesize that the 12-week online lifestyle-coaching program will be viable, and a full-scale study can proceed.

this study will investigate the feasibility of a 12-weeks online lifestyle (nutrition and physical behavior) coaching program through a mobile app (liven) compared to standard treatment for people with type 2 diabetes. this study will be done in two phases; the first phase is the usability study (phase1), in which the user friendliness of the application will be assessed, and any technical flaws will be resolved prior and during the second phase. the second phase of the study will consist of adapting a diabetes educational material and assessing the feasibility of the program (phase2). the investigators hypothesize that the 12-week online lifestyle-coaching program will be feasible, and a full-scale study can proceed.

Eligibility criteria:
inclusion criteria: * adults, aged 18 years or older * arabic speakers * capable of utilizing smartphones * diagnosed with t2dm * poor glycemic control: a1c \> 7.5% exclusion criteria: * individuals using insulin injection * individuals suffering from disorders that might affect intervention (e.g. amputation, enucleation of the eye, or end-stage kidney disease) * women who are pregnant or breastfeeding * individuals diagnosed with other types of diabetes (such as type i or mody)

Keywords: type 2 diabetes management mhealth lifestyle management program
early stereotactic gamma knife radiosurgery to residual tumor after surgery of newly diagnosed glioblastoma

Conditions: Glioblastoma

Summary: gamma gbm is a single-arm phase ii trial that prospectively measures the progression-free survival time after addition of an early gamma knife boost to areas of residual tumor to standard-of-care (surgery, chemo-radiotherapy, chemotherapy).

glioblastomas are highly malignant brain tumors that recur about 6 months after treatment. most recurrences develop at the edge of the surgical margin and a common reason for an early recurrence of a glioblastoma is when tumors are not completely resected. this may be the case when intraoperative neuro-monitoring indicates that further resection would impair certain motor functions. physicians can identify residual tumor in early (24-72h after surgery) postoperative mri scans and could treat these regions. however, this treatment would not be a part of the recommended standard of care and thus, any further treatment of this areas will need a clinical trial. the aim of this trial is to evaluate if the use of another modality to deplete these areas of residual tumor identified in early postoperative mri scans will provide a relevant benefit in terms of progression-free survival (which means a prolongation of the time that patients do not experience a re-growth of the tumor). the modality is termed "radiosurgery", which is a non-invasive technique to delete cells without using a blade but a highly focused beam of gamma rays. the machine that focusses these rays (like a magnifying glass that can focus light), is called 'gamma knife'. gamma knife radiosurgery is a safe and effective treatment for a plethora of malignant and benign brain tumors and the technique is used since the 1950s and there has been a continuous improvement of precision and patient comfort up to now.

Eligibility criteria:
inclusion criteria: * age ≥ 18 * karnofsky performance status score ≥ 60 * histology must be glioblastoma (frozen sections during surgery) * radiographic proof of residual tumor * informed consent * adequate birth control (e.g., oral contraceptives) exclusion criteria: * any previous cranial radiotherapy * histology inconclusive or low(er)-grade astrocytoma * contraindications for chemo- or radiotherapy * bleeding or clotting disorders * contraindications for mri or ct scans

Keywords: glioblastoma radiosurgery gamma knife
electronic cigarettes as a harm reduction strategy among people living with hiv/aids

Conditions: Nicotine Addiction

Summary: this is a research study to understand and determine the effectiveness of electronic cigarettes versus nicotine replacement therapy in adults who smoke and also live with hiv/aids in effort to reduce cigarette smoking.

people living with hiv/aids (plwha) are known to have exceptionally higher rate of cigarette smoking and very low quit rates compared to the general population. although a primary rationale for conducting this study is reducing health disparities among plwha, there is a potential benefit of the proposed work from a prevention perspective given that combustible cigarette smoking is an independent risk factor for non-adherence to art and may decrease the effectiveness of haart. smoking-related illnesses are leading causes of non-hiv/aids-related deaths among people living with hiv/aids (plwha). electronic cigarettes (e-cigarettes) could help people reduce the harm of combustible cigarette (cc) through reductions in number of cigarettes per day (cpd) or quitting cc completely by addressing both nicotine and behavioral dependence. unlike cc, ec are not associated with coronary heart disease or myocardial infarction. the purpose is to identify barriers and facilitators, as well as assess preliminary effectiveness of e-cigarettes as a harm reduction strategy among plwha.

Eligibility criteria:
inclusion criteria: * current combustible cigarette (cc) smokers (more than 5 packs in a lifetime; smokes 4 or more days/week), * smokes at least 10 cigarettes per day on days they smoke cc. * motivated to quit smoking (at least a 5 on a 10-point likert scale). * must be able to provide consent * agree to be randomized and followed-up with, * reside in new york city * be willing to use an e-cigarette or nrt for 12 weeks. exclusion criteria: * are pregnant (as determined by urine test) or breastfeeding (self-reported), * state diagnosis of any medical condition (angina/heart disease) precluding use of nicotine patch or gum, or by self-report in screening questionnaire * reporting using nrts or e-cigarettes or within the last 30 days * have untreated/are undergoing current treatment for psychiatric illness or cognitive impairment at time of initial screening as determined by the subjects' primary care doctor or a licensed study team member in screening * report a history of severe or untreated cardiopulmonary disease such as asthma or emphysema.
randomized study of conditioning of fludarabine combined with single or dual alkylating agents in myeloid malignancies

Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndromes

Summary: fludarabine and busulfan becomes standard conditioning regimen for adult patients with acute myeloid leukemia (aml) or myelodysplasia syndrome (mds). the overall relapse rate is 15\~20%. more recently, the investigators demonstrated that conditioning regimen with dual alkylating agents consistent of fludarabine, busulfan and melphalan achieved a low incidence of relapse (\<10%). this multiple-center randomize study is aim to compare the transplantation outcome in adult patients with aml/mds undergoing allo-hsct with conditioning regimen of flu-bu4 vs. flu-bu-mel.

fludarabine and busulfan was considered as myeloablative but reduced toxicity regimen and became as the mainstay of conditioning regimen for adult patients with acute myeloid leukemia (aml) or myelodysplasia syndrome (mds). the disease relapse remained as major cause of treatment failure. in general, the cumulated incidence of relapse (cir) is about 15\~20% dependent on the risk of patients undergoing allogeneic stem cell transplantation (allo-hsct). conditioning regimen with dual alkylating agents such as fludarabine, busulfan and thiotepa (tbf) showed decreased risk of relapse in myeloid malignancies. more recently, the investigators demonstrated that conditioning regimen with dual alkylating agents consistent of fludarabine, busulfan and melphalan could achieve a low incidence of relapse (2 year cir \<10%). in this multiple-center randomize study, the aim is to compare the transplantation outcome in adult patients with aml/mds undergoing allo-hsct with conditioning regimen of flu-bu vs. flu-bu-mel.

Eligibility criteria:
inclusion criteria: * acute myeloid leukemia (acute promyelocytic leukemia excluded) in 1st complete remission * myelodysplasia syndrome with bone marrow blast \>5% and remaining less than 20% at transplantation * patients with hla matched sibling donor, 9-10 matched unrelated donor or haplo-identical related donors * inform consent provided exclusion criteria: * aml patients with active cns or extramedullary diseases * patients with active viral, bacterial or fungal infection * patients with hepatitis b virus \>1x103 copy/ml * patients with abnormal liver function, renal function, respiratory or cardiac dysfunction * patients with uncontrolled mental disorders * patients with hiv

Keywords: conditioning regimen, melphalan, busulfan, fludarabine